AstraZeneca

28 Maj 2021 08:01

Tagrisso approved in the EU for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80%
AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after com

21 Maj 2021 08:01

AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan

AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2.

19 Maj 2021 23:02

AstraZeneca ASCO 2021 data support ambition to revolutionise cancer outcomes by treating earlier and transforming the patient experience

AstraZeneca will present new data underscoring its ambition to redefine cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting, 4 to 8 June 2021.

12 Maj 2021 10:04

Results of Annual General Meeting held on 11 May 2021

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 – 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

Issued capital
As at 7 May 2021, the number of issued shares of the Company was 1,312,762,006 ordinary

12 Maj 2021 09:31

AstraZeneca shareholders vote in favour of proposed acquisition of Alexion

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
THIS IS AN ANNOUNCEMENT AND NOT A CIRCULAR OR PROSPECTUS OR EQUIVALENT DOCUMENT FOR THE PURPOSES OF THE UK PROSPECTUS REGULATION RULES OR THE UK AND EU PROSPECTUS REGUL

1 Maj 2021 06:46

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.

30 April 2021 08:04

AstraZeneca PLC:s resultatrapport för första kvartalet 2021

Stabilt resultat möjliggör fortsatta investeringar för långsiktigt hållbar tillväxt
AstraZeneca levererade en stabil intäktstillväxt på 15% (11% i fasta valutakurser1) till 7 320 MUSD under kvartalet. Exklusive bidraget från pandemivaccinet mot COVID-19 ökade intäkterna med 11% (7% i fasta valutakurser) till 7 045 MUSD. De övergripande resultaten under kvartalet stärkte bolagets lönsamhet och k

26 April 2021 08:11

Selumetinib recommended for approval in the EU by CHMP as the first medicine for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas

AstraZeneca and MSD’s selumetinib has been recommended for conditional marketing authorisation in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above.1

26 April 2021 08:08

Tagrisso recommended for approval in the EU by CHMP for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

AstraZeneca’s Tagrisso (osimertinib) has been recommended for marketing authorisation in the European Union for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.

26 April 2021 08:02

Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants

The MELODY Phase III trial for nirsevimab met its primary endpoint of a statistically significant reduction in the incidence of medically attended lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) compared to placebo in healthy late preterm and term infants (35 weeks or more) during their first RSV season.1

16 April 2021 13:01

AstraZeneca receives US clearance of proposed acquisition of Alexion

AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals, Inc (Alexion) has achieved an important step toward completion, having cleared US Federal Trade Commission review. This follows the conclusion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

14 April 2021 08:01

Tagrisso approved in China for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

AstraZeneca’s Tagrisso (osimertinib) has been approved in China for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent, with or without adjuvant chemotherapy as recommended by the patient’s physician.

Nyhetsarkiv

Om AstraZeneca